Sonova (OTCMKTS:SONVY) Shares Gap Up – Still a Buy?

Sonova Holding (OTCMKTS:SONVY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $53.33, but opened at $55.44. Sonova shares last traded at $54.94, with a volume of 1,372 shares changing hands.

Analysts Set New Price Targets

SONVY has been the topic of several research reports. BNP Paribas initiated coverage on shares of Sonova in a research report on Monday, October 20th. They set an “underperform” rating on the stock. Royal Bank Of Canada raised shares of Sonova to a “moderate buy” rating in a research note on Tuesday, November 18th. Zacks Research lowered shares of Sonova from a “hold” rating to a “strong sell” rating in a report on Tuesday, December 9th. Finally, Rothschild Redb upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Sonova Stock Performance

The company’s fifty day moving average is $51.30 and its two-hundred day moving average is $55.06. The company has a quick ratio of 0.91, a current ratio of 1.24 and a debt-to-equity ratio of 0.51.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.